Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Oxford BioDynamics brings prostate cancer test EpiSwitch PSE to the UAE

Oxford BioDynamics has entered into a partnership with the Dubai London Clinics & Hospitals Group (DLCH) to offer the prostate cancer test EpiSwitch PSE across DLCH’s clinic and hospital network in the United Arab Emirates. Patient blood samples will be collected at DLCH facilities and analyzed at Oxford BioDynamics’ laboratory in the UK; the clinical workflow has been validated by both partners. The agreement is the first commercial rollout of the test in the Gulf region; market launch, local market development and collaboration with payers are intended to gradually increase test volumes. » More on de.investing.com
Oxford BioDynamics secures £9.15m through conditional share issue

Oxford BioDynamics raised about £9.15m by placing 9.15 billion new ordinary shares at £0.001 each; after fees roughly £8.4m is expected. The proceeds are intended to fund platform partnerships for EpiSwitch‑Orion, expansion of the prostate cancer test, development of a test for response to checkpoint inhibitors and completion of a colorectal cancer study. Without the financing, cash is expected to be exhausted in early September 2026; the transaction requires shareholder approval (AGM 26 Aug.) and AIM approval (27 Aug.). The company reported a significant capital loss under the Companies Act, and the board is considering alternative financing options, a sale or an orderly wind‑down if the proposal is rejected. » More on de.investing.com
Oxford BioDynamics partners with MK Commercial Group to expand US sales

Oxford BioDynamics has signed a sales agreement with MK Commercial Group to strengthen US distribution of EpiSwitch PSE. Initially seven field sales advisors will be deployed, with the number able to rise to as many as 35 to cover key population centers such as New Jersey, Washington D.C., Virginia, Georgia and Chicago. According to the company, the test for triage after elevated PSA levels has a positive predictive value of 93% and a specificity of 97% and is intended to reduce unnecessary biopsies. The sales representatives will operate under the commercial management of Oxford BioDynamics and will complement the existing sales infrastructure in Frederick, Maryland. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, OXFORD BIODYNAMICS LS-,01 Aktie has already paid €0.0195 in dividends. The last payout was in January 2022.

Financials

In the last quarter, OXFORD BIODYNAMICS LS-,01 Aktie had revenue of €785.98K and net profit of -€5.11M

(EUR)	March 2026	YoY
Revenue	785.98K	-
Gross profit	-276.87K	-
Net profit	-5.11M	-
EBITDA	-4.73M	-

Fundamentals

Metric	Value
Market capitalization	€2.74M
Number of shares	2.13B
52-week high/low	€0.00407 - €0.000956
Dividends	No
Beta	-0.13
P/E ratio	-0.27
PEG ratio	0.00
P/B ratio	1.26
P/S ratio	1.92

Company profile

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.